The Global Theranostics Market Size is to Grow from USD 1.9 Billion in 2023 to USD 3.3 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 5.68% during the projected period.
Theranostics is a type of pharmaceutical treatment used in combination with diagnostics to maximize efficacy, safety, and expedite the discovery of new drugs. It is also known as integrated medicine, pharmacodiagnostics, companion diagnostics, and Dx/Rx partnership. It is the application of drugs in addition to diagnostic techniques.
Theranostics is the process of combining medicinal treatment and diagnostics to expedite the creation of more affordable and effective medications. a quickly developing subject that the healthcare industry and regulatory organizations find intriguing. A number of factors are driving the global theranostics market, including the rising incidence of cancer globally and the resulting need for more specialized and potent therapies.
The identification of certain cancer biomarkers allows for the customization of treatment regimens for individual patients. Combining medicine and diagnosis, or theranostics, can lessen side effects and increase the efficacy of cancer therapies.
The oncology segment is expected to hold the largest share of the global theranostics market during the predicted timeframe.
The theranostics market is classified by disease into neurological disorders, cardiovascular diseases, oncology disorders, immunological disorders. Among these, the oncology disorders segment is expected to hold the largest share of the global theranostics market during the predicted timeframe.
The growing number of cancer patients globally has led to the development of a method based on theranostic nanoparticles. To cut down on treatment delays, the mechanism combines prescription drugs with diagnostic techniques. The specifically cancer-targeting medication-encapsulated nanoparticle-based treatment tracks and identifies biological systems.
The PCR segment is expected to hold the largest share of the global theranostics market during the forecast period.
Based on the technology, the global theranostics market is divided into PCR, In Situ Hybridization (ISH), Immunohistochemistry (IHC). Among these, the PCR segment is expected to hold the largest share of the global theranostics market during the forecast period.
Theranostics market growth is predicted to be driven by the creation and use of increasingly individualized medical solutions, with an emphasis on hospitals and clinics. The growing prevalence of chronic illnesses and the growing need for specialized therapeutic and diagnostic options are projected to drive growth in the theranostics market over the coming years.
North America is anticipated to hold the largest share of the global theranostics market over the predicted timeframe.
Companies covered: F Hoffman La Roche, Thermo Fisher Scientific Inc., GE Healthcare, Agilent Technologies, Qiagen NV, Foundation Medicine, Leica Biosystems Nussloch GmBH, Pfizer, Inc., Beckman Coulter, Inc., Focus Diagnostics, Illumina, Inc., Abbott Laboratories, Myriad Genetics, Inc., AmeriPath, Inc.
